Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TOX NEG Trial: Oral Vancomycin vs Placebo in C. difficile
NCT03388268Phase 4Completed
- Sponsor
- Washington University School of Medicine
- Start
- Dec 2017
- Primary completion
- Jan 2021
- Modality
- Cyclic Peptides, Antimicrobial Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of vancomycin in Clostridium difficile infection (CDI), sponsored by Washington University School of Medicine. Started Dec 2017; status: completed.
02
Drugs
vancomycin
03
Conditions
Clostridium difficile infection (CDI)
Beyond the preview
Go deeper on NCT03388268.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03388268.